Published in Int J Gen Med on July 30, 2009
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 22.64
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol (2001) 3.44
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat (1998) 2.42
Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) (1982) 1.80
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol (1993) 1.58
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg (1978) 1.33
Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg (1991) 1.29
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol (2003) 1.25
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res (1990) 1.23
Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol (1994) 1.19
In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids (1988) 1.00
Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol (1990) 1.00
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res (2000) 0.97
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol (2001) 0.96
Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs (2002) 0.94
Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat (2001) 0.94
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer (2001) 0.92
Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer (1992) 0.86
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol (2003) 0.83
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev (2004) 0.82
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol (2002) 0.81
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol (2003) 0.81
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol (2003) 0.79
Treatment of breast cancer in elderly patients. J Surg Oncol (1995) 0.78
ACOG committee opinion: Tamoxifen and endometrial cancer. Int J Gynaecol Obstet (2001) 0.78
[Neoadjuvant endocrine therapy for breast cancer: an overview]. Bull Cancer (2004) 0.77
Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer (2002) 0.77
Pre-operative endocrine therapy for postmenopausal women: when and why? Ann Oncol (2001) 0.76
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol (2005) 3.34
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene (2001) 2.32
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer (2002) 1.76
Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg (2001) 1.57
Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol (2007) 1.50
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg (2003) 1.40
[Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment]. Gynecol Obstet Fertil (2003) 1.40
The "definitive" trial of surgical cytoreduction in advanced-stage ovarian cancer. Int J Gynecol Cancer (2013) 1.39
[Is there still a place for extemporaneous exam in breast cancer?]. Gynecol Obstet Fertil (2006) 1.37
Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine (2007) 1.28
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol (2007) 1.27
Temozolomide and unusual indications: review of literature. Cancer Treat Rev (2012) 1.24
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology (2003) 1.23
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res (2009) 1.19
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol (2009) 1.18
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer (2003) 1.17
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther (2010) 1.17
Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer (2009) 1.16
Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg (2003) 1.13
Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer (1994) 1.11
Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer (2010) 1.11
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol (2007) 1.07
Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2007) 1.05
Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol (2000) 1.04
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol (2002) 1.01
Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. Int J Gynecol Cancer (2012) 0.99
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol (2009) 0.99
Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun (2005) 0.99
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol (2012) 0.99
Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol (2008) 0.98
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol (2008) 0.98
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol (2008) 0.98
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer (2003) 0.97
Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev (2013) 0.97
Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2008) 0.97
Personalized cancer medicine and the future of pathology. Virchows Arch (2011) 0.97
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat (2005) 0.94
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer (2009) 0.93
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer (2012) 0.92
Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology (2008) 0.92
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Int J Cancer (1999) 0.91
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol (2012) 0.90
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection. Mol Hum Reprod (2004) 0.90
Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat (2002) 0.89
Ovarian epithelial dysplasia after ovulation induction: time and dose effects. Hum Reprod (2008) 0.89
Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer (2001) 0.89
Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat (2009) 0.89
Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol (2014) 0.88
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer (2010) 0.88
A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J (2008) 0.88
Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer. Oncol Rep (2003) 0.88
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer (2003) 0.88
Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res (2010) 0.87
Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol (2008) 0.86
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol (2014) 0.86
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs (2005) 0.85
Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol (2003) 0.85
[Male breast cancer: a review]. Bull Cancer (2009) 0.85
Creation of the miami pouch during laparoscopic-assisted pelvic exenteration: the initial experience. Int J Gynecol Cancer (2009) 0.85
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer (2006) 0.85
High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant (1998) 0.84
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs (2008) 0.84
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer (2006) 0.84
[The use of breast cancer subtype classification to predict local and distant recurrence. A review]. Cancer Radiother (2008) 0.84
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer (2010) 0.84
Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis. Cancer (2009) 0.84
Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis. Crit Rev Oncol Hematol (2013) 0.84
Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest (2009) 0.83
Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol (2005) 0.83
Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist (2002) 0.83
A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats. PLoS One (2013) 0.83
Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer (2010) 0.83